Federated Hermes
EDIT icon

Federated Hermes’s Editas Medicine EDIT Stock Holding History

Federated Hermes’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73K Hold
1,150
– – ﹤0.01% 1948
2026
Q1 		$2.84K Buy
1,150
+403
+54% +$853 ﹤0.01% 1948
2025
Q4 		$1.53K Buy
+747
New +$2.16K ﹤0.01% 1988
2023
Q4 		– Sell
-1,941
Closed -$15.1K – 2081
2023
Q3 		$15.1K Hold
1,941
– – ﹤0.01% 1786
2023
Q2 		$16K Buy
+1,941
New +$16.9K ﹤0.01% 1801
2023
Q1 		– Sell
-8,292
Closed -$73.5K – 2157
2022
Q4 		$73.5K Buy
8,292
+2,376
+40% +$26.1K ﹤0.01% 1663
2022
Q3 		$72K Buy
5,916
+229
+4% +$3.57K ﹤0.01% 1639
2022
Q2 		$67K Buy
+5,687
New +$76.2K ﹤0.01% 1651
2021
Q3 		– Sell
-232,192
Closed -$13.2M – 2246
2021
Q2 		$13.2M Sell
232,192
-408,079
-64% -$15.1M 0.02% 580
2021
Q1 		$26.9M Sell
640,271
-1,077,804
-63% -$61.4M 0.05% 421
2020
Q4 		$120M Buy
1,718,075
+11,775
+0.7% +$484K 0.25% 105
2020
Q3 		$47.9M Buy
1,706,300
+2,000
+0.1% +$65.1K 0.11% 217
2020
Q2 		$50.4M Buy
1,704,300
+267,500
+19% +$6.99M 0.12% 189
2020
Q1 		$28.5M Hold
1,436,800
– – 0.08% 261
2019
Q4 		$42.5M Hold
1,436,800
– – 0.09% 246
2019
Q3 		$32.7M Buy
1,436,800
+679,600
+90% +$16.8M 0.08% 254
2019
Q2 		$18.7M Buy
757,200
+151,700
+25% +$3.62M 0.05% 372
2019
Q1 		$14.8M Buy
605,500
+39,800
+7% +$901K 0.04% 426
2018
Q4 		$12.9M Buy
565,700
+69,800
+14% +$1.9M 0.04% 412
2018
Q3 		$15.8M Buy
495,900
+185,568
+60% +$6M 0.04% 408
2018
Q2 		$11.1M Buy
310,332
+55,232
+22% +$1.96M 0.03% 419
2018
Q1 		$8.46M Buy
255,100
+222,300
+678% +$7.92M 0.02% 478
2017
Q4 		$1.01M Buy
+32,800
New +$826K ﹤0.01% 1223

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Federated Hermes's EDIT Position: Q2 2026 in Review

Federated Hermes held its Editas Medicine (EDIT) position steady in Q2 2026 at 1,150 shares worth $3.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1948.

Federated Hermes first reported a position in EDIT in Q4 2017 and has held it in 23 quarters since. The position peaked at $120M in Q4 2020. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Federated Hermes held 1,150 shares of Editas Medicine worth $3.73K as of Q2 2026.
  • Federated Hermes left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1948 holding.
  • Federated Hermes first reported a position in Editas Medicine in Q4 2017 and has held it in 23 quarters since.
  • Federated Hermes's Editas Medicine position peaked at $120M in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.